A proteomic landscape of diffuse-type gastric cancer.

TitleA proteomic landscape of diffuse-type gastric cancer.
Publication TypeJournal Article
Year of Publication2018
AuthorsGe, S, Xia, X, Ding, C, Zhen, B, Zhou, Q, Feng, J, Yuan, J, Chen, R, Li, Y, Ge, Z, Ji, J, Zhang, L, Wang, J, Li, Z, Lai, Y, Hu, Y, Li, Y, Li, Y, Gao, J, Chen, L, Xu, J, Zhang, C, Jung, SYun, Choi, JMin, Jain, A, Liu, M, Song, L, Liu, W, Guo, G, Gong, T, Huang, Y, Qiu, Y, Huang, W, Shi, T, Zhu, W, Wang, Y, He, F, Shen, L, Qin, J
JournalNat Commun
Volume9
Issue1
Pagination1012
Date Published2018 Mar 08
ISSN2041-1723
KeywordsChemoradiotherapy, Adjuvant, Datasets as Topic, DNA Mutational Analysis, Down-Regulation, Exome, Follow-Up Studies, Gastrectomy, Genes, Neoplasm, Humans, Immunohistochemistry, Mutation, Neoadjuvant Therapy, Neoplasm Proteins, Neoplasm Staging, Oligonucleotide Array Sequence Analysis, Prognosis, Proteomics, Sequence Analysis, DNA, Signal Transduction, Stomach, Stomach Neoplasms, Survival Analysis, Tandem Mass Spectrometry, Up-Regulation
Abstract

The diffuse-type gastric cancer (DGC) is a subtype of gastric cancer with the worst prognosis and few treatment options. Here we present a dataset from 84 DGC patients, composed of a proteome of 11,340 gene products and mutation information of 274 cancer driver genes covering paired tumor and nearby tissue. DGC can be classified into three subtypes (PX1-3) based on the altered proteome alone. PX1 and PX2 exhibit dysregulation in the cell cycle and PX2 features an additional EMT process; PX3 is enriched in immune response proteins, has the worst survival, and is insensitive to chemotherapy. Data analysis revealed four major vulnerabilities in DGC that may be targeted for treatment, and allowed the nomination of potential immunotherapy targets for DGC patients, particularly for those in PX3. This dataset provides a rich resource for information and knowledge mining toward altered signaling pathways in DGC and demonstrates the benefit of proteomic analysis in cancer molecular subtyping.
DOI10.1038/s41467-018-03121-2
Alternate JournalNat Commun
PubMed ID29520031
PubMed Central IDPMC5843664
Grant ListS10 OD023469 / OD / NIH HHS / United States
U01 MH105026 / MH / NIMH NIH HHS / United States

Similar Publications

Semancik CS, Zhao N, Koestler DC, Boerwinkle E, Bressler J, Buchsbaum RJ, et al.. DNA Methylation-Derived Immune Cell Proportions and Cancer Risk in Black Participants. Cancer Res Commun. 2024;4(10):2714-2723.
Dwarshuis N, Tonner P, Olson ND, Sedlazeck FJ, Wagner J, Zook JM. StratoMod: predicting sequencing and variant calling errors with interpretable machine learning. Commun Biol. 2024;7(1):1316.
Behera S, Belyeu JR, Chen X, Paulin LF, Nguyen NQuynh H, Newman E, et al.. Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk. BMC Med Genomics. 2024;17(1):255.